MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
Khiem A Tran,1,* Michelle Y Cheng,1,* Anupam Mitra,1 Hiromi Ogawa,1 Vivian Y Shi,1 Laura P Olney,1 April M Kloxin,2 Emanual Maverakis1 1Department of Dermatology, University of California, Davis, Sacramento, CA, USA; 2Department of Chemical and Biomolecular Engineering, University...
Saved in:
Main Authors: | Tran KA (Author), Cheng MY (Author), Mitra A (Author), Ogawa H (Author), Shi VY (Author), Olney LP (Author), Kloxin AM (Author), Maverakis E (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2015-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MEK inhibitors for the treatment of NRAS mutant melanoma
by: Sarkisian S, et al.
Published: (2018) -
Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma
by: Qian Zhao, et al.
Published: (2022) -
Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
by: Raphael Reinhard, MD, et al.
Published: (2018) -
Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
by: Pópulo H, et al.
Published: (2021) -
Clinico-economic analysis of PD-1 inhibitors and combinations of BRAF and MEK inhibitors for the treatment of metastatic melanoma with a BRAF V600 gene mutation
by: D. Yu. Belousov, et al.
Published: (2018)